Business Wire - ADVISORY/TargetRx CEO Mike Luby to Keynote at WBR’s PharmaForce Conference; Pharma Sales and Marketing Expert to Discuss Sales Force Quality Metrics and…
TargetRx–
WHO: TargetRx CEO, Mike Luby, will deliver a keynote presentation
and lead the “Sales Force Strategies and Leadership
Development” track at the upcoming WBR PharmaForce Conference.
WHAT: In his presentation, “Evaluating Sales Force Performance:
Quantity vs. Quality,” Luby will use case studies and personal
experiences working with major pharmaceutical companies to
evaluate the industry’s method of measuring sales force
effectiveness, which has traditionally focused almost entirely
on quantity metrics, as the area of quality was not entirely
understood. Luby will outline how sales force quality metrics
can more accurately reveal how well a sales force is
executing, based on the major drivers of physician
prescribing.
At WBR PharmaForce, leaders from the pharmaceutical,
biopharmaceutical and health care industries will gather to
discuss a range of topics, including sales force optimization,
physician access, incentive compensation, sales training and
leadership, data analysis and sales force technology. With
keynote presenters from top pharmaceutical companies,
including Pfizer and Eli Lilly, the event provides attendees
with insight into how to implement successful training models
to maximize market share, overcome the difficulties in
accessing customers, design and administer optimal incentive
compensation plans, and employ best practices for augmenting
sales force strategies using the latest technologies.
WHEN: The WBR PharmaForce Conference will be held September 19-21,
2006.
Luby’s presentation is scheduled for Wednesday, September 20,
at 9:55 a.m.
WHERE: Doral Forrestal Conference Center & Spa, Princeton, NJ
About Mike Luby
Michael J. Luby is a co-founder of TargetRx. Luby brings more than 15 years of pharmaceutical marketing and sales experience from a variety of therapeutic areas to his role as President, CEO and Board Member of the Company. As the CEO since the Company’s inception in 1999, Luby has succeeded in raising over $50 million in capital, expanding the TargetRx team to more than 100 employees, and securing clients in the majority of the top 30 pharmaceutical companies worldwide. Luby is also the lead author on TargetRx’s patented method of analyzing the effectiveness of marketing and sales strategies. Luby has been honored with the Philadelphia Business Journal’s “40 Under 40″ award and selected by PharmaVOICE as one of the 100 most inspiring people in life sciences. TargetRx has also received the Eastern Technology Council’s Enterprise Award for Life Sciences Growth Company of the Year.
Prior to starting TargetRx, Luby spent 10 years at Merck & Co., Inc., where he created and executed marketing strategies for both the specialty and mass markets. The concept for TargetRx was born from his dissatisfaction with the lack of insightful, predictive and actionable marketing information from external sources during his tenure at Merck. As senior director of marketing, worldwide for new products at Merck, Luby spearheaded global pre-launch strategy and planning activities for two late-stage development products. He also served as director of new product marketing, managing the marketing strategy of early-stage drug development candidates and evaluating the potential of in-licensing opportunities from biotech companies. Luby’s previous roles included marketing management and research analyst positions for successful drugs such as Fosamax, now a multi-billion dollar brand, Vasotec and Prilosec, as well as positions focusing on marketing to managed care customers, including an assignment at Merck-Medco Managed Care.
Luby holds a B.A. in economics from Dartmouth College and an M.B.A. from the Wharton School of the University of Pennsylvania.
About TargetRx
TargetRx is a pharmaceutical sales and marketing effectiveness company that provides actionable insight to pharmaceutical companies to help them effectively sell and market their products and improve their financial performance. TargetRx has developed a highly predictive, database of physician attitudes that it uses in combination with its patented analytic methods to provide pharmaceutical companies with powerful “leading indicators” of how their sales and marketing initiatives will affect physician prescribing. TargetRx benchmarks performance, identifies immediate improvement opportunities and predicts future performance for its clients. TargetRx works with the majority of the top 30 pharmaceutical companies in the U.S. For further information, visit www.targetrx.com.
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
